Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3675 Market Street PHILADELPHIA PA 19104 |
Tel: | N/A |
Website: | https://www.amicusrx.com |
IR: | See website |
Key People | ||
Bradley Lewis Campbell President, Chief Executive Officer, Director | Simon N.R. Harford Chief Financial Officer | Samantha Whiteman Prout Chief Accounting Officer, Controller |
Jeffrey P. Castelli Chief Development Officer | David M. Clark Chief People Officer | Ellen S. Rosenberg Chief Legal Officer, Corporate Secretary |
Business Overview |
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer. |
Financial Overview |
For the fiscal year ended 31 December 2023, Amicus Therapeutics, Inc. revenues increased 21% to $399.4M. Net loss decreased 36% to $151.6M. Revenues reflect Ex-US segment increase of 18% to $252.4M, U.S segment increase of 27% to $146.9M. Lower net loss reflects Research and development - Balancing val decrease of 48% to $130.9M (expense), Loss on impairment of assets decrease of 83% to $1.1M (expense). |
Employees: | 517 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,236M as of Dec 31, 2023 |
Annual revenue (TTM): | $399.36M as of Dec 31, 2023 |
EBITDA (TTM): | -$68.20M as of Dec 31, 2023 |
Net annual income (TTM): | -$151.58M as of Dec 31, 2023 |
Free cash flow (TTM): | -$76.53M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $101.66M as of Dec 31, 2023 |
Shares outstanding: | 295,382,614 as of Feb 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |